
Observation on the Curative Effect of Madopar Combined with Pramipexole in the Treatment of Parkinson’s Diseases
Author(s) -
Yongting Yu,
Min Yang,
Ruihui Chen,
Hongbing Chen
Publication year - 2017
Publication title -
advanced emergency medicine
Language(s) - English
Resource type - Journals
ISSN - 2315-456X
DOI - 10.18686/aem.v6.80
Subject(s) - pramipexole , dopamine , parkinson's disease , acetylcholine , dopaminergic , medicine , disease , neurotransmitter , levodopa , striatum , neuroscience , psychology , central nervous system
Parkinson’s disease is a common neurological degenerative disease in the elderly. The clinical manifestations are static tremor, increased muscle tone, slow movement, abnormal posture gait, and severe symptoms of loss of self-care. Parkinson’s disease has become a burden to not only patient, but also to his family and to the society. Normal human brain neurotransmitter dopamine and acetylcholine are in a balanced state, the two antagonism can maintain normal body function. The pathological changes of patients with Parkinson’s disease is degeneration and apoptosis of dopaminergic neurons in striatum, resulting in a significant reduction in dopamine levels, and thus lead to an imbalance in the effects of dopamine and acetylcholine, and a decrease in dopamine resistance to acetylcholine Parkinson’s disease symptoms. As such, this article will focus on the analysis of the Madopar and pramipexole in the treatment of Parkinson’s disease symptoms.